Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

ation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), and orthostatic hypotension (7% vs 5%).

Please see the full Prescribing Information including Boxed Warning for SEROQUEL XR available at www.astrazeneca-us.com/cgi-bin/az_pi.cgi?country=us&product=seroquelxr .

IMPORTANT SAFETY INFORMATION FOR SEROQUEL IMMEDIATE RELEASE TABLETS

SEROQUEL is indicated for the treatment of depressive episodes in bipolar disorder; acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; and schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL is not approved for the treatment of patients with dementia-related psychosis. (See Boxed Warning.)

Suicidality in children and adolescents -- antidepressants increased the risk of suicidal thinking and behavior (4% vs 2% for placebo) in short-term studies of 9 antidepressant drugs in children and adolescents with major depressive disorder and other psychiatric disorders. Patients started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL is not approved for use in pediatric patients. (See Boxed Warning.)

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including SEROQUEL. Rare cases of NMS have been reported with SE
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/29/2015)... VANCOUVER, British Columbia and ... DelMar Pharmaceuticals, Inc. (OTCQX: ... focused on developing and commercializing proven cancer therapies ... data at the American Association of Cancer ... on the potential for its lead product ...
(Date:5/29/2015)...  Eli Lilly and Company (NYSE: LLY ) ... they have entered into a clinical trial collaboration to ... anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ... medicine. The planned study will assess the combination as ... The Phase I study is expected to establish ...
(Date:5/29/2015)... 2015  World-renowned prostate surgeon and New York Urologist, Dr. ... of MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive ... Center at Lenox Hill Hospital is the only center ... New York City . We,ve seen tremendous improvement ... The use of an MRI makes for a much more ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... UK pharma group GlaxoSmithKline reports a 2% ... underlying sales momentum. In an interview with ... CFO Simon Dingemans review Q2 results including overall delivery ... a review of the recently implemented Drug Performance Units. ...
... Pharmaceuticals, Inc. announced the following news today concerning the future ... On December 31, 2011, the FDA ban ... a propellant will become effective. Primatene® Mist has ... symptoms for over 40 years. The ban on the sale ...
Cached Medicine Technology:Statement on Availability of Primatene® Mist CFC 2
(Date:5/29/2015)... (PRWEB) May 30, 2015 “In ... changing local and federal regulations, we provide education ... their patients who are suffering from pain, within ... Srinivas Nalamachu, MD, professor of rehabilitation medicine and ... in Overland Park, Kansas. , A new flight ...
(Date:5/29/2015)... What does community do? , According to a ... to plant gardens, to teach young people, to laugh, ... issues. Community invites everyone to help improve lives for ... Does" was commissioned by The Denver Foundation, the largest ... the foundation’s Annual Celebration in May. At just over ...
(Date:5/29/2015)... 2015 The third annual Newport 10 ... closed to new registration, starts outside the east wall ... competitive running event demonstrates the power of combining professional ... benefit – in this case, historic preservation. , ... famed Ocean Drive and passes by many Bellevue Avenue ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 According to a ... in 10 full-time workers has a substance abuse problem - ... more than 111,500 adults with full-time jobs, revealed that 9.5% ... the previous year. (1) The National Council on Alcoholism and ... per year, and an estimated 70% of the 14.8 million ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4
... eye of now co-editor Rick Drake and colleagues at the ... now the highest ranking journal in science education? If ... correct! As AAA publisher Wiley-Blackwell put it in a ... as the number 1 ranked journal in Education, Scientific Disciplines." ...
... scientists at Duke University Medical Center and Johns Hopkins ... of drug therapy to treat the second most common ... been looking for the primary cancer genes involved in ... that held the probable mutations, but not the particular ...
... Summer for most people means time spent outdoors, which ... arthropod-borne diseases, such as "rickettsial diseases" infectious diseases ... fleas, ticks and mites. Now a $1.6 million ... enable an entomologist at the University of California, Riverside ...
... Southwestern Medical Center researchers may suggest new strategies for successful ... such as leukemia, lymphoma and myeloma. The study, published ... the first time that adult blood stem cells can be ... rejection. It also opens up further studies in stem cell ...
... and Zappos.com are famous for their "work hard, play ... employees healthier too? According to a Tel Aviv University ... health benefits. Dr. Sharon Toker of the ... School of Business Administration says that employees who believe ...
... By Ellin Holohan HealthDay Reporter , THURSDAY, ... antidepressants than ever before to deal with everyday stress, ... to patients with no mental health diagnosis, a new ... Lexapro are now the third most widely prescribed group ...
Cached Medicine News:Health News:AAA journal rockets to top of science education category 2Health News:Elusive gene mutations found for malignant brain tumor 2Health News:UC Riverside entomologist to study diseases transmitted by ticks 2Health News:UC Riverside entomologist to study diseases transmitted by ticks 3Health News:Hang out at the water cooler, live longer 2Health News:Hang out at the water cooler, live longer 3Health News:Americans' Use of Antidepressants On the Rise: Study 2Health News:Americans' Use of Antidepressants On the Rise: Study 3
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... is a dedicated high performance ... applications. Genegnome completely automates the ... It provides superbly accurate results ... use, unique image analysis algorithms ...
... Chrono-log's wide range of Platelet ... capabilities to meet particular needs. Single, ... available, with chart recorder outputs or ... the Chrono-log Optical aggregometers, which measure ...
Medicine Products: